Boston Biomedical Inc., of Cambridge, Mass., reported data from a phase Ib/II trial testing napabucasin in metastatic colorectal cancer (mCRC) and pancreatic adenocarcinoma (mPDAC) at the European Society of Medical Oncology 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain.